MANF is increased naturally with Valproic Acid
Valproic acid up-regulates melatonin MT1 and MT2 receptors and neurotrophic factors CDNF and MANF in the rat brain.
Because he is using many different molecules not just one.
"We have several small molecules that can potentially delay the progression of Wolfram syndrome. Three of them are FDA-approved small molecules, and one of them is a FDA-approved peptide."
Ihub post #108122
A must watch video on GDNF on Parkinsons patients.
MANF could be greater
Will they try other vaccines besides ZMAPP?
But what exactly is the secret serum? It’s a question practically everyone’s been asking. The answer: Something the National Institutes of Health and Mapp, the biopharmaceutical firm that manufactured it, are largely keeping mum about. As far as we know, Gupta has the most details regarding the serum’s effect and what it does. As he put it in his CNN report:
The medicine is a three-mouse monoclonal antibody, meaning that mice were exposed to fragments of the Ebola virus and then the antibodies generated within the mice's blood were harvested to create the medicine. It works by preventing the virus from entering and infecting new cells.
Baltimore companies Profectus BioSciences and Paragon Bioservices, as well as researchers at the U.S. Army Medical Research Institute for Infectious Diseases at Fort Detrick in Frederick and the National Institutes of Health in Bethesda, have been part of efforts that have shown a handful of Ebola vaccine candidates are effective in monkeys.
Meanwhile, poor communication and understanding of the virus is allowing it to spread faster than efforts to contain it, according to the World Health Organization. That could mean the outbreak is far from over, said Dr. Randal Schoepp, a scientist at the Army's Frederick institute, in an interview from Liberia.
"I believe we're only seeing a small portion of the actual cases out there," Schoepp said of the outbreak. "It's putting a tremendous stress on the medical system, and there aren't even enough medical staff to take samples."
What was the PPV (the positive predictive value) of this test?
In the Georgetown blood test these numbers were only 32%
"Blood Test Accuracy Not Easily Measured" MedPage Today March 17, 2014
In my story about the Georgetown test, I used their figures of 90% sensitivity and 90% specificity (that is, yielding 10% false-negative and 10% false-positive results), and assumed that the actual 3-year conversion rate from cognitively healthy to impaired was 5%. That figure came from the group's own report (28 participants converted out of an initial sample of 525), but it's also consistent with rates seen in other studies. For example, a prospective observational study conducted in Leipzig, Germany, found an annual conversion rate to mild impairment of about 1.5% in participants, ages 80-84.
So let's look at an assay with sensitivity and specificity rates of 90%, to be used in a population of 1,000 people in which 5% will actually convert to cognitive impairment. We know that 50 of these 1,000 will convert and 950 will not. Of those 50 converters, 10% will falsely test negative, and, of the 950 nonconverters, 10% will falsely test positive.
That means the testing program produces a total of 140 positive results, 45 of which are correct and 95 false. The PPV is just the fraction of total positives that are correct -- in this example, 45/140 or 32%.
That's still terrible, given that there is currently no "gold standard" test that can confirm an individual patient's positive result, and there is also no treatment currently or likely in the near future.
"Blood Test Accuracy Not Easily Measured" (google it)
By John Gever, Deputy Managing Editor, MedPage Today
The best hope for the Georgetown cognitive impairment test may be as part of a Framingham-type scoring system that also takes account of other risk factors, such age, gender, education level, personal history of head injury, family history of dementia, and APOE genotype. Combining all such factors could improve the specificity and sensitivity to the point where the PPV reaches a clinically useful level, which in this application would probably need to be close to 90%.
Seems Lympro combined with a similar Framingham scoring system would still do better than the Georgetown test if used with such a scoring system.
When will the numbers be released?
Coming soon to a city near you.
“while the possibility of infected persons entering the U.S. remains low, the Centers for Disease Control and Prevention (CDC) advises that healthcare providers in the U.S. should consider EVD [Ebola virus disease] in the differential diagnosis of febrile illness, with compatible symptoms, in any person with recent (within 21 days) travel history in the affected countries and consider isolation of those patients meeting these criteria, pending diagnostic testing.” In CDC-speak this is mostly caution and not fear—but it is the first time they have moved this tone into the first paragraph of an Ebola advisory, and the first time they have carpet-bombed practitioners nation-wide with emails and faxes.
younger than 25?
what about the rest of the age groups?
Dr Gatherer, a specialist in the evolution of viruses, said the panic sparked by the death of Mr Sawyer in Lagos, is justified.
'Anyone on the same plane could have become infected because Ebola is easy to catch,' he said.
He said: "Only about 10 per cent recover. The outlook is pretty bleak. They will need to trace everyone on the passenger list and isolate them as a precaution.
'I believe they have contacted about half so far but the others could be anywhere else in the world now.
'There is no treatment - nothing you can do yourself. It's in the lap of the gods if you're lucky to be one of the few who survive.
go to daily mail uk for story and pics
But several small biotech companies and U.S. university departments are developing potential vaccines.
Tekmira Pharmaceuticals, which teamed up with the U.S. Department of Defense on an injectable drug for Ebola, started their initial Phase I trial in healthy volunteers in January.
U.S.-based Inovio and privately held Vaxart are among those with experimental vaccines in animal testing, while GlaxoSmithKline last year acquired Swiss vaccine firm Okairos with an early-stage Ebola product.
'Fast-track the Ebola drug': U.S. under pressure to give potentially life-saving medication the green light as experts warn of global pandemic
A petition has been launched urging the U.S. Food and Drug Administration to fast-track a new Ebola drug
At first it sounded like they were holding off on releasing info tomorrow but that is not the case.
"We very much look forward to sharing the interim results tomorrow with the community."
He's trying to get a date with Melinda Richter who is head of Janssen Labs' three sites in San Diego, Cambridge and a new one in San Fransisco. And one hot chic!
According to the American Academy of Clinical Research’s Task Force on the Treatment and Prevention of Intraepithelial Neoplasia, 50% objective regression rate with a new treatment agent is considered clinically meaningful.
In Phase I the low dose was .6 ml, mid dose 2ml. and high dose of 6ml. but in phase II the dose was 1ml. will a phase IIb be started for a stronger dose, or will a phase III go for a higher dose, seems good results should be improved with a tweak in dosing, any thoughts?
Do these look like good numbers?
The test had an overall accuracy 95%. Sensitivity was 1 (95% CI: 0.89-1), specificity 0.94 (95% CI: 0.83-0.98), Positive Predictive Value 0.94 (95% CI: 0.81-0.98), and Negative Predictive Value 1 (95% CI: 0.91-1)
Will they run a small INO-3112 trial for Cervical Dysplasia, with this new combo?
INO-3112 DNA vaccine (VGX-3100 and INO-9012)
And what is known of the 10% that do survive, have they built up an immunity against Ebola or can they be infected once again?